Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | ADH5 | P11766 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26898524 | 0.75 | DHODH (0.40) | ALDH1A1DHODHALOX5RARBADH5 | |
| SCHEMBL27021641 | 0.72 | ALDH1A1 (0.40) | ALDH1A1DHODHALOX5RARBADH5 | |
| SCHEMBL1947351 | 0.69 | DHODH (0.37) | ALDH1A1DHODHALOX5RARBADH5 | |
| SCHEMBL18603139 | 0.69 | ALDH1A1 (0.49) | ALDH1A1ALOX5RARBADH5KMO | |
| SCHEMBL26898475 | 0.69 | DHODH (0.40) | ALDH1A1DHODHALOX5RARBPARP1 | |
| SCHEMBL15479756 | 0.67 | DHODH (0.48) | ALDH1A1DHODHPARP1L3MBTL1 | |
| SCHEMBL2646013 | 0.66 | ALDH1A1 (0.57) | ALDH1A1XDHSLC22A12ALOX5RARB | |
| SCHEMBL22273714 | 0.66 | ALOX5 (0.63) | ALDH1A1XDHSLC22A12ALOX5RARB | |
| SCHEMBL27362952 | 0.65 | ALDH1A1 (0.44) | ALDH1A1DHODHRARBADH5PARP1 | |
| SCHEMBL26856096 | 0.64 | THRB (0.43) | ALDH1A1DHODHALOX5RARBKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203219-B1 | SUBSTITUTED BENZAMIDINES AS ANTIBACTERIAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2015-02-25 | — | — | EP | disclosed |
| EP-2203219-B1 | SUBSTITUTED BENZAMIDINES AS ANTIBACTERIAL AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2015-02-25 | — | — | EP | disclosed |
| US-8415383-B2 | Substituted benzamidines as antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-04-09 | — | — | US | disclosed |
| US-8415383-B2 | Substituted benzamidines as antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-04-09 | — | — | US | disclosed |
| US-8415383-B2 | Substituted benzamidines as antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-04-09 | — | — | US | disclosed |
| US-20100298388-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD. (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298388-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD. (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298388-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD. (GB) | 2010-11-25 | — | — | US | disclosed |
| EP-2203219-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | Biota Europe Ltd (GB) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009040507-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009040507-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298388-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | ALK, CBR3, CBR1 | ALDH1A1 626/4885DHODH 1164/4885XDH 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.